Curaleaf Holdings CURLF
OTC CURLF
$9.99 +0.39 (+4.06%)
As of: Aug 21, 2026 · 3:59 PM EDT

Curaleaf Holdings (CURLF) Cash from Financing Activities (2019 - 2024)

Curaleaf Holdings (CURLF) posted quarterly Cash from Financing Activities of -$6.6 million for Q4 2024, up 61.27% year-over-year from -$4.1 million in Q1 2024, and up 46.11% quarter-over-quarter from -$12.2 million in Q3 2024.

Curaleaf Holdings (CURLF) Cash from Financing Activities (2019 - 2024) Analysis & Trends

Curaleaf Holdings' Cash from Financing Activities history runs 6 years deep, the most recent figure standing at -$6.6 million for Q4 2024.

  • In Q4 2024, Cash from Financing Activities rose 61.27% year-over-year to -$6.6 million; the TTM figure through Dec 2024 stood at -$54.1 million (up 19.26% YoY), while the FY2025 annual figure was -$73.5 million, down 35.86% from the prior year.
  • Cash from Financing Activities for Q4 2024 stood at -$6.6 million, up from -$12.2 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $28.6 billion in Q2 2023, with the low at -$28.6 billion in Q1 2023.
  • The 5-year median for Cash from Financing Activities is $1.7 million (2020), against an average of $27.4 million.
  • Peak annual rise in Cash from Financing Activities reached 59634.52% in 2023, while the deepest fall reached 171254.23% in 2023.
  • Curaleaf Holdings' Cash from Financing Activities stood at $3.4 million in 2020, then soared by 2674.62% to $95.2 million in 2021, then slumped by 59.54% to $38.5 million in 2022, then plunged by 144.09% to -$17.0 million in 2023, then surged by 61.27% to -$6.6 million in 2024.
  • Business Quant data shows CURLF's Cash from Financing Activities at -$6.6 million in Q4 2024, -$12.2 million in Q3 2024, and -$15.7 billion in Q2 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Haleon 44.51 Bn 43.55 Bn - -
2 Teva Pharmaceutical Industries 43.52 Bn 39.86 Bn 2.15 Bn -1.00 Mn
3 Zoetis 32.43 Bn 30.75 Bn 1.05 Bn -813.00 Mn
4 Takeda Pharmaceutical 28.63 Bn 22.83 Bn 5.10 Bn -1.13 Bn
5 United Therapeutics 21.87 Bn 19.21 Bn 683.80 Mn 122.40 Mn
6 Viatris 18.98 Bn 18.09 Bn 1.46 Bn -1.24 Bn
7 Neurocrine Biosciences 15.43 Bn 15.04 Bn 935.80 Mn 63.40 Mn
8 Elanco Animal Health 12.02 Bn 11.49 Bn 798.00 Mn -74.00 Mn
9 Dr Reddys Laboratories 10.14 Bn 9.98 Bn - -
10 Curaleaf Holdings 2.61 Bn 2.52 Bn 169.91 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2024 -6.58 Mn
Dec 31, 2024 -6.58 Mn
Sep 30, 2024 -12.21 Mn
Sep 30, 2024 -12.21 Mn
Jun 30, 2024 -15.73 Bn
Jun 30, 2024 -15.73 Bn
Mar 31, 2024 15.70 Bn
Mar 31, 2024 15.70 Bn
Dec 31, 2023 -16.99 Mn
Dec 31, 2023 -16.99 Mn
Sep 30, 2023 5.06 Mn
Sep 30, 2023 5.06 Mn
Jun 30, 2023 28.59 Bn
Jun 30, 2023 28.59 Bn
Mar 31, 2023 -28.65 Bn
Mar 31, 2023 -28.65 Bn
Dec 31, 2022 38.53 Mn
Dec 31, 2022 38.53 Mn
Sep 30, 2022 -27.89 Mn
Sep 30, 2022 -27.89 Mn